Logo image of BAYN.DE

BAYER AG-REG (BAYN.DE) Stock Fundamental Analysis

FRA:BAYN - Deutsche Boerse Ag - DE000BAY0017 - Common Stock - Currency: EUR

27.51  +0.17 (+0.62%)

Fundamental Rating

3

Taking everything into account, BAYN scores 3 out of 10 in our fundamental rating. BAYN was compared to 50 industry peers in the Pharmaceuticals industry. BAYN has a bad profitability rating. Also its financial health evaluation is rather negative. BAYN is cheap, but on the other hand it scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

BAYN had positive earnings in the past year.
In the past year BAYN had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: BAYN reported negative net income in multiple years.
In the past 5 years BAYN always reported a positive cash flow from operatings.
BAYN.DE Yearly Net Income VS EBIT VS OCF VS FCFBAYN.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5B -5B -10B

1.2 Ratios

BAYN's Return On Assets of -2.98% is on the low side compared to the rest of the industry. BAYN is outperformed by 68.00% of its industry peers.
BAYN's Return On Equity of -10.03% is on the low side compared to the rest of the industry. BAYN is outperformed by 68.00% of its industry peers.
Industry RankSector Rank
ROA -2.98%
ROE -10.03%
ROIC N/A
ROA(3y)-0.5%
ROA(5y)-1.93%
ROE(3y)-2.08%
ROE(5y)-7.52%
ROIC(3y)N/A
ROIC(5y)N/A
BAYN.DE Yearly ROA, ROE, ROICBAYN.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 -20 -30

1.3 Margins

In the last couple of years the Operating Margin of BAYN has declined.
BAYN has a worse Gross Margin (53.99%) than 68.00% of its industry peers.
In the last couple of years the Gross Margin of BAYN has declined.
The Profit Margin and Operating Margin are not available for BAYN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 53.99%
OM growth 3Y-18.1%
OM growth 5Y-4.34%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.21%
GM growth 5Y-1.81%
BAYN.DE Yearly Profit, Operating, Gross MarginsBAYN.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60

More info and screens

2

2. Health

2.1 Basic Checks

BAYN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BAYN remains at a similar level compared to 1 year ago.
Compared to 5 years ago, BAYN has about the same amount of shares outstanding.
The debt/assets ratio for BAYN has been reduced compared to a year ago.
BAYN.DE Yearly Shares OutstandingBAYN.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M
BAYN.DE Yearly Total Debt VS Total AssetsBAYN.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20B 40B 60B 80B 100B

2.2 Solvency

BAYN has an Altman-Z score of 0.84. This is a bad value and indicates that BAYN is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.84, BAYN is doing worse than 72.00% of the companies in the same industry.
The Debt to FCF ratio of BAYN is 6.81, which is on the high side as it means it would take BAYN, 6.81 years of fcf income to pay off all of its debts.
BAYN's Debt to FCF ratio of 6.81 is in line compared to the rest of the industry. BAYN outperforms 46.00% of its industry peers.
A Debt/Equity ratio of 1.08 is on the high side and indicates that BAYN has dependencies on debt financing.
BAYN has a Debt to Equity ratio of 1.08. This is in the lower half of the industry: BAYN underperforms 64.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.08
Debt/FCF 6.81
Altman-Z 0.84
ROIC/WACCN/A
WACC6.17%
BAYN.DE Yearly LT Debt VS Equity VS FCFBAYN.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B 40B

2.3 Liquidity

BAYN has a Current Ratio of 1.25. This is a normal value and indicates that BAYN is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of BAYN (1.25) is worse than 70.00% of its industry peers.
BAYN has a Quick Ratio of 1.25. This is a bad value and indicates that BAYN is not financially healthy enough and could expect problems in meeting its short term obligations.
BAYN has a worse Quick ratio (0.79) than 64.00% of its industry peers.
Industry RankSector Rank
Current Ratio 1.25
Quick Ratio 0.79
BAYN.DE Yearly Current Assets VS Current LiabilitesBAYN.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B

More info and screens

3

3. Growth

3.1 Past

BAYN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -24.72%.
BAYN shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -5.27% yearly.
The Revenue has decreased by -0.92% in the past year.
Measured over the past years, BAYN shows a small growth in Revenue. The Revenue has been growing by 1.37% on average per year.
EPS 1Y (TTM)-24.72%
EPS 3Y-8.12%
EPS 5Y-5.27%
EPS Q2Q%-11.7%
Revenue 1Y (TTM)-0.92%
Revenue growth 3Y1.87%
Revenue growth 5Y1.37%
Sales Q2Q%-0.2%

3.2 Future

BAYN is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 2.07% yearly.
The Revenue is expected to grow by 1.07% on average over the next years.
EPS Next Y-8.65%
EPS Next 2Y-1.15%
EPS Next 3Y1.51%
EPS Next 5Y2.07%
Revenue Next Year-0.13%
Revenue Next 2Y0.7%
Revenue Next 3Y1.06%
Revenue Next 5Y1.07%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
BAYN.DE Yearly Revenue VS EstimatesBAYN.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 10B 20B 30B 40B 50B
BAYN.DE Yearly EPS VS EstimatesBAYN.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2 4 6

More info and screens

7

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 5.83, which indicates a rather cheap valuation of BAYN.
Based on the Price/Earnings ratio, BAYN is valued cheaper than 96.00% of the companies in the same industry.
BAYN is valuated cheaply when we compare the Price/Earnings ratio to 27.41, which is the current average of the S&P500 Index.
BAYN is valuated cheaply with a Price/Forward Earnings ratio of 5.57.
98.00% of the companies in the same industry are more expensive than BAYN, based on the Price/Forward Earnings ratio.
BAYN's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 35.19.
Industry RankSector Rank
PE 5.83
Fwd PE 5.57
BAYN.DE Price Earnings VS Forward Price EarningsBAYN.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, BAYN is valued a bit cheaper than the industry average as 78.00% of the companies are valued more expensively.
100.00% of the companies in the same industry are more expensive than BAYN, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 4.68
EV/EBITDA 7.43
BAYN.DE Per share dataBAYN.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.15%
EPS Next 3Y1.51%

More info and screens

0

5. Dividend

5.1 Amount

BAYN has a yearly dividend return of 0.40%, which is pretty low.
Compared to an average industry Dividend Yield of 3.00, BAYN is paying slightly less dividend.
Compared to an average S&P500 Dividend Yield of 2.35, BAYN's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 0.4%

5.2 History

The dividend of BAYN decreases each year by -45.34%.
Dividend Growth(5Y)-45.34%
Div Incr Years0
Div Non Decr Years3
BAYN.DE Yearly Dividends per shareBAYN.DE Yearly Dividends per shareYearly Dividends per share 2019 2020 2021 2022 2023 2024 2025 0.5 1 1.5 2 2.5

5.3 Sustainability

BAYN has negative earnings and hence a negative payout ratio. The dividend may be in danger.
DP-4.03%
EPS Next 2Y-1.15%
EPS Next 3Y1.51%
BAYN.DE Yearly Income VS Free CF VS DividendBAYN.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5B -5B -10B

More info and screens

BAYER AG-REG

FRA:BAYN (7/14/2025, 5:36:15 PM)

27.51

+0.17 (+0.62%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-13 2025-05-13/bmo
Earnings (Next)08-06 2025-08-06
Inst Owners41.07%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap27.03B
Analysts71.72
Price Target28.75 (4.51%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0.4%
Yearly Dividend0.13
Dividend Growth(5Y)-45.34%
DP-4.03%
Div Incr Years0
Div Non Decr Years3
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)2.63%
Min EPS beat(2)1.86%
Max EPS beat(2)3.41%
EPS beat(4)3
Avg EPS beat(4)-1.9%
Min EPS beat(4)-17.26%
Max EPS beat(4)4.42%
EPS beat(8)5
Avg EPS beat(8)-2.92%
EPS beat(12)8
Avg EPS beat(12)-2.14%
EPS beat(16)12
Avg EPS beat(16)1.92%
Revenue beat(2)1
Avg Revenue beat(2)0.4%
Min Revenue beat(2)-0.98%
Max Revenue beat(2)1.79%
Revenue beat(4)2
Avg Revenue beat(4)-0.64%
Min Revenue beat(4)-3.42%
Max Revenue beat(4)1.79%
Revenue beat(8)2
Avg Revenue beat(8)-2.63%
Revenue beat(12)4
Avg Revenue beat(12)-2.01%
Revenue beat(16)8
Avg Revenue beat(16)-0.66%
PT rev (1m)2.46%
PT rev (3m)4.2%
EPS NQ rev (1m)-1.12%
EPS NQ rev (3m)-11.26%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.27%
Revenue NQ rev (1m)1.24%
Revenue NQ rev (3m)-0.84%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.25%
Valuation
Industry RankSector Rank
PE 5.83
Fwd PE 5.57
P/S 0.58
P/FCF 4.68
P/OCF 3.18
P/B 0.83
P/tB N/A
EV/EBITDA 7.43
EPS(TTM)4.72
EY17.16%
EPS(NY)4.93
Fwd EY17.94%
FCF(TTM)5.88
FCFY21.39%
OCF(TTM)8.65
OCFY31.45%
SpS47.41
BVpS33.03
TBVpS-18.52
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -2.98%
ROE -10.03%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 53.99%
FCFM 12.41%
ROA(3y)-0.5%
ROA(5y)-1.93%
ROE(3y)-2.08%
ROE(5y)-7.52%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)7.82%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-18.1%
OM growth 5Y-4.34%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.21%
GM growth 5Y-1.81%
F-Score3
Asset Turnover0.43
Health
Industry RankSector Rank
Debt/Equity 1.08
Debt/FCF 6.81
Debt/EBITDA 4.37
Cap/Depr 30.76%
Cap/Sales 5.84%
Interest Coverage N/A
Cash Conversion 106.2%
Profit Quality N/A
Current Ratio 1.25
Quick Ratio 0.79
Altman-Z 0.84
F-Score3
WACC6.17%
ROIC/WACCN/A
Cap/Depr(3y)34.81%
Cap/Depr(5y)41.62%
Cap/Sales(3y)5.85%
Cap/Sales(5y)5.86%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-24.72%
EPS 3Y-8.12%
EPS 5Y-5.27%
EPS Q2Q%-11.7%
EPS Next Y-8.65%
EPS Next 2Y-1.15%
EPS Next 3Y1.51%
EPS Next 5Y2.07%
Revenue 1Y (TTM)-0.92%
Revenue growth 3Y1.87%
Revenue growth 5Y1.37%
Sales Q2Q%-0.2%
Revenue Next Year-0.13%
Revenue Next 2Y0.7%
Revenue Next 3Y1.06%
Revenue Next 5Y1.07%
EBIT growth 1Y-214.77%
EBIT growth 3Y-16.56%
EBIT growth 5Y-3.03%
EBIT Next Year63.3%
EBIT Next 3Y21.17%
EBIT Next 5Y10.6%
FCF growth 1Y380.55%
FCF growth 3Y22.16%
FCF growth 5Y-3.69%
OCF growth 1Y99.13%
OCF growth 3Y12.83%
OCF growth 5Y-2.09%